Policies to enhance prescribing efficiency in Europe: Findings and future implications

Frontiers in Pharmacology

Volumn JAN, Issue , 2011, Pages

  Godman, Brian ^a,b,c   Shrank, William ^d   Andersen, Morten ^c   Berg, Christian ^e   Bishop, Iain ^f   Burkhardt, Thomas ^g   Garuoliene, Kristina ^h,i   Herholz, Harald ^j   Joppi, Roberta ^a,k   Kalaba, Marija ^l   Laius, Ott ^m   Lonsdale, Julie ⁿ   Malmström, Rickard E ^c   Martikainen, Jaana E ^o   Samaluk, Vita ^p   Sermet, Catherine ^q   Schwabe, Ulrich ^r   Teixeira, Inês ^s   Tilson, Lesley ^t   Tulunay, F Cankat ^u   Vlahović Palčevski, Vera ^v   Wendykowska, Kamila ^w   Wettermark, Bjorn ^c,x   Zara, Corinne ^y   Gustafsson, Lars L ^c   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^f INFORMATION SERVICES DIVISION   (United Kingdom)

^g Hauptverband der Osterreichischen Sozialversicherungstrager   (Austria)

^h VILNIUS UNIVERSITY   (Lithuania)

ⁱ National Health Insurance Fund   (Lithuania)

^j Kasemarzliche Vereinigung Hessen   (Germany)

^k Pharmaceutical Drug Department   (Italy)

^l Republic Institute for Health Insurance   (Serbia)

^m State Agency of Medicines   (Estonia)

ⁿ NHS North Lancashire   (United Kingdom)

^o SOCIAL INSURANCE INSTITUTION   (Finland)

^p Health Insurance Institute   (Slovenia)

^q Institute de Recherche et Documentation en Économie de la Santé   (France)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s CEFAR Centre for Health Evaluation and Research   (Portugal)

^t ST JAMES S HOSPITAL   (Ireland)

^u ANKARA UNIVERSITY   (Turkey)

^v KBC RIJEKA   (Croatia)

^w HTA CONSULTING   (Poland)

^x STOCKHOLM COUNTY COUNCIL   (Sweden)

^y C Agy Hlth Technol Assess Res   (Spain)

more..

Author keywords

Drugs; Economics; Efficiency; Generics; Pharmaceuticals; Sustainability

Indexed keywords

GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; OMEPRAZOLE; PROTON PUMP INHIBITOR; SIMVASTATIN;

ARTICLE; COST CONTROL; DRUG COST; DRUG INDUSTRY; DRUG PROGRAM; DRUG RESEARCH; DRUG UTILIZATION; EUROPE; HEALTH CARE POLICY; HUMAN; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY;

EID: 79952781964     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2010.00141     Document Type: Article

References (93)

1. Adamski, J., Godman, B., Ofierska-Sujkowska, G., Osinska, B., Herholz, H., Wendykowska, K., Laius, O., Jan, S., Sermet, C., Zara, C., Kalaba, M., Gustafsson, R., Garuoliene, K., Haycox, A., Garattini, S., and Gustafsson, L. L. (2010). Review of risk sharing schemes for pharmaceuticals: considerations, critical evaluation and recommenda- tions for European payers. BMC Health Serv. Res.10, 153. doi: 10.1186/1472-6963-10-153
2. AFSSAPS. (2005). Prise en Charge Therapeutic du Patient Dyslipidemique. Available at: http://www.afssaps.fr/var/afssaps_site/storage/original/application/da2c055ce7845afe44d7-aaca7c3f4de8.pdf [Accessed 20 July 2010].
3. Allenet, B., and Barry, H. (2003). Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 com- munity pharmacists. Pharm. World Sci. 25, 197-202.
4. Barrett, A., Roques, T., Small, M., and Smith, R. (2006). How much will Herceptin really cost? BMJ 33, 1118-1120.
5. Barry, M., Usher, C., and Tilson, L. (2010). Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoecon. Outcomes Res. 10, 239-245.
6. Barton, S. (2001). Using clinical evidence. BMJ 322, 503-504.
7. Beishon, J., McBride, T., and Scharaschkin, A. (2007). Prescribing Costs in Primary Care. National Audit Office. Available at: http://www.nao.org.uk/publications/0607/prescribing_costs_in_primary_c.aspx?alreadysearchfor=yes [Accessed 20 June 2010].
8. Bergman, U., Gimsson, A., Wahba, A., and Westerholm, B. (eds). (1979). Studies in Drug Utilization - Methods and Applications. Copenhagen: World Health Organization Regional Publications.
9. Bero, L., Grilli, R., Grimshaw, J., Harvey, E., Oxman, A., Tomson, M., On Behalf of the Cochrane Effective Practice and Organisation of Care Review Group. (1998). Getting research into practice. BMJ 317, 465-468.
10. Birkett, D. (2002). The future of ATC/ DDD and drug utilisation research. WHO Drug Inf. 16, 238-240.
11. Blaszczyk, P., Janiszewski, R., and Bondaryk, K. (2007). Poland - Pharma Profile; Pharmaceutical Pricing and Reimbursement Information. Available at: http://ppri.oebig.at/Downloads/Results/Poland_PPRI_2007.pdf [Accessed 20 August 2010].
12. Cameron, A., Ewen, M., Ross-Degnan, D., Ball, D., and Laing, R. (2009). Medicine prices, availability and affordability in 36 developing and middle-income countries; a secondary analysis. Lancet 273, 240-249.
13. Caroll, J. (2005). Plans struggle for con- trol of speciality pharma costs. Manag. Care 14, 41-48.
14. Coma, A., Zara, C., Godman, B., Augusti, A., Diogene, E., Wettermark, B., and Haycox, A. (2009). Policies to enhance the effi- ciency of prescribing in the Spanish Catalan Region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9, 569-581.
15. Cooke, J., Mason, A., Drummond, M., and Towse, A. (2005). Medication manage- ment in English national health service hospitals. Am. J. Health Syst. Pharm. 62, 189-195.
16. Cramer, J., Benedict, A., Muszabek, N., Keskinaslan, A., and Khan, Z. M. (2008). The significance of compliance and persistence in the treatment of dia- betes, hypertension and dyslipidaemia: a review. Int. J. Clin. Pract. 62, 76-87.
17. DoH. (2006). Good Practice Guidance on Managing the Introduction of New Healthcare Interventions and Links to NICE Technology Appraisal Guidance. Available at: www.dh.gov.uk/en/Pub-licationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_064983 [Accessed 20 July 2010].
18. Do H. (2008). How to Put NICE Guidance into Practice and Improve the Health and Wellbeing of Communities: Practical Steps for Local Authorities. ISBN 1-84629-861-X. Available at: http://www.nice.org.uk/media/163/5A/HowputNICEguidancepracticelocal.pdf [Accessed 20 July 2010].
19. Do H. (2010). Better Care Better Value Indicator. Low Cost PPI Prescribing. Available at: http://www.productivity.nhs.uk/Def_IncreasingLowCostPPIPrescribing.aspx [Accessed 3 July 2010].
20. Duerden, M., and Hughes, D. (2010). Generic and therapeutic substitutions in the UK: are they a good thing? Br. J. Clin. Pharmacol. 70, 335-341.
21. Elshaug, A. G., Moss, J. R., Littlejohns, P., Karnon, J., Merlin, T. L., and Hiller, J. E. (2009). Identifying existing health care services that do not provide value for money. Med. J. Aust. 190, 269-273.
22. Eriksson, G., and Lundin, D. (2009). The Review of Medicines for Lipid Disorders. Available at: http://www.tlv.se/Upload/Genomgangen/summary-lipids.pdf [Accessed 20 July 2010].
23. Ess, S., Schneeweiss, S., and Szucs, T. (2003). European healthcare poli- cies for controlling drug expenditure. Pharmacoecnomics 21, 89-103.
24. Fattore, G., and Jommi, C. (2008). The last decade of Italian pharmaceutical policy - instability or consolidation? Pharmacoeconomics 26, 5-15.
25. Fein, O. (2010). Keep the single payer vision. Med. Care 48, 759-760.
26. Festoy, H., Sveen, K., Yu, L.-M., Gjönnes, L., and Gregersen, T. (2008). Norway - Pharmaceutical Pricing and Reimbursement Information. Available at: http://ppri.oebig.at/Downloads/Results/Norway_PPRI_2008.pdf [Accessed 3 August 2010].
27. Frank, R. (2007). The ongoing regulation of generic drugs. N. Engl. J. Med. 357, 1993-1996.
28. Garattini, S., Bertele, V., Godman, B., Wettermark, B., and Gustafsson, L. L. (2008). Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138.
29. Godman, B., Bucsics, A., Burkhardt, T., Haycox, A., Seyfried, H., and Wieninger, P. (2008a). Insight into recent reforms and initiatives in Austria; implications for key stake- holders. Expert Rev. Pharmacoecon. Outcomes Res. 8, 357-371.
30. Godman, B., Haycox, A., Schwabe, U., Joppi, R., and Garattini, S. (2008b). Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98.
31. Godman, B., Shrank, W., Wettermark, B., Andersen, M., Bishop, I., Burkhardt, T., Garuoliene, K., Kalaba, M., Laius, O., Joppi, R., Sermet, C., Schwabe, U., Teixeira, I., Tulunay, F. C., Wendykowska, K., Zara, C., and Gustafsson, L. L. (2010a). Use of generics - a critical cost containment measure for all healthcare profes- sionals in Europe? Pharmaceuticals 3, 2470-2494.
32. Godman, B., Bucsics, A., Burkhardt, T., Schmitzer, M., Wettermark, B., and Wieninger, P. (2010b). Initiatives to enhance renin-angiotensin prescrib- ing efficiency in Austria: impact and implications for other countries Expert Rev. Pharmacoecon. Outcomes Res. 10, 199-207.
33. Godman, B., Shrank, W., Andersen, M., Berg, C., Bishop, I., T. Burkhardt, T., Garuoliene, K., Herholz, H., Joppi, R., Kalaba, M., Laius, O., McGinn, D., Samaluk, V., Sermet, C., Schwabe, U., Teixeira, I., Tilson, L., Tulunay, F. C., Vlahović-Palčevski, V., Wendykowska, K., Wettermark, B., Zara, C., and Gustafsson, L. L. (2010c). Comparing policies to enhance the utilisation generics across Europe: impact and global implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 707-722.
34. Godman, B., and Wettermark, B. (2009a). "Impact of reforms to enhance the quality and efficiency of statin pre- scribing across 20 European coun- tries," in 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, eds. D. Webb and S. Maxwell, Medimond International Proceedings - Medimond s.t.l., Pianoro. ISBN 978-88-7587-549-7, 65-69.
35. Godman, B., and Wettermark, B. (2009b). "Trends in consumption and expendi- ture of proton pump inhibitors (PPIs) in 20 European countries," in 9th Congress of the European Association for Clinical Pharmacology and Therapeutics, Edinburgh, eds D. Webb and S. Maxwell, Medimond International Proceedings - Medimond s.t.l., Pianoro. ISBN 978-88-7587-549-7, 71-75.
36. Godman, B., Wettermark, B., Hoffman, M., Andersson, K., Haycox, A., and Gustafsson, L. L. (2009a). Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83.
37. Godman, B., Schwabe, U., Selke, G., and Wettermark, B. (2009b). Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid- lowering drugs. Pharmacoeconomics 27, 1-4.
38. Godman, B., Burkhardt, T., Bucsics, A., Wettermark, B., and Wieninger, P. (2009c). Impact of recent reforms in Austria on utilisation and expendi- ture of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9, 475-484.
39. Gouya, G., Reichart, B., Bidner, A., Weissenfels, R., and Wolzt, M. (2008). Partial reimbursement of prescription chages for generic drugs reduces costs fr both healh insurance and patients. Wien. Klin. Wochenschr. 120, 89-95.
40. Grol, R., and Grimshaw, J. (2003). From best evidence to best practice: effective implementation of change in patients' care. Lancet 362, 1225-1230.
41. Gumbs, P., Verschuren, W., Souverein, P., Mantel-Teeuwisse, A. K., de Wit, G. A., de Boer, A., and Klungel, O. H. (2007). Society already achieves economic benefits from generic substitution but fails to do the same for therapeu- tic substitution. Br. J. Clin. Pharmacol. 64, 680-685.
42. Heikkilä, R., Mäntyselkä, P., Hartikainen-Herranen, K., and Ahonen, R. (2007). Customers' and physicians' opinions of experiences with generic substitution during the first year in Finland. Health Policy (New York) 82, 366-374.
43. Hyde, R. (2007). Doctors to pay for patients' medicine in Germany. Lancet 370, 1118.
44. Jack, A. (2008). Balancing Big Pharma's books. BMJ 336, 418-419.
45. Jones, I. M., Greenfield, S., and Bradley, P. (2001). Prescribing new drugs: quali- tative study of influences on consult- ants and general practioners. BMJ 323, 378-381.
46. Kjoenniksen, I., Lindbaek, M., and Grannas, A. (2006). Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm. World Sci. 28, 284-289.
47. Kopp, C., and Vandevelde, F. (2006). Use of international nonproprietary names (INN) among members. ISDB Newsl. 20, 2-4.
48. Krska, J., and Godman, B. (2010). Medicines Management in Pharmacy in Public Health, 2010. London: RPS Publishing (in press).
49. Lee, T., and Emanuel, E. (2008). Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med. 359, 333-335.
50. Magrini, N., Formoso, G., Marata, A., Capelli, O., Maestri, E., Voci, C., Nonino, F., Brunetti, M., Paltrinieri, B., Maltoni, S., Magnano, L., Bonacini, M. I., Daya, L., and Viani, N. (2007). Randomised controlled trials for evaluating the prescribing impact of information meetings led by phar- macists and of new information for- mats in general practice in Italy. BMC Health Services Research 7, 158. doi: 10.1186/1472-963-7-158
51. Martikainen, J., Saastamoinen, L., Korhonen, M., Enlund, H., and Helin-Salmivaara, A. (2010). Impact of restricted reimbursement on the use of statins in Finland. Med. Care 48, 761-766.
52. McGinn, D., Godman, B., Lonsdale, J., Way, R., Wettermark, B., and Haycox, A. (2010). Initiatives to enhance the effi- ciency of statin and proton pump inhib- itor prescribing in the UK; impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 73-85.
53. MeReC Extra. (2006). NICE Appraises Statins. Available at: http://www.npc.co.uk/ebt/merec/cardio/cdlipids/resources/merec_extra_no21.pdf [Accessed 20 July 2010].
54. Moon, J., Flett, A., Godman, B., Grosso, A., and Wierzbicki, A. (2010). Getting bet- ter value from the NHS drug budget. BMJ 341, c6449.
55. National Institute for Health and Clinical Excellence. (2006). Statins for the Prevention of Cardiovascular Events. Technology Appraisal 94 and Related Costing Template and Report. Available at: http://www.nice.org.uk/ [Accessed 20 July 2010].
56. Norman, C., Zarrinkoub, R., Hasselström, J., Godman, B., Granath, F., and Wettermark, B. (2009). Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326.
57. Office of Fair Trading (UK). (2007). The Pharmaceutical Price Regulation System: An OFT Study. Annexe A: Market for Prescription Pharmaceuticals in the NHS. London: The Office of Fair Trading [online]. Available at: http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885a.pdf [Accessed 3 July 2010].
58. Pegler, C., and Underhill, J. (2005). Evaluating promotional material from industry: an evidence-based approach. Pharm. J. 274, 271-274.
59. Peura, S., Rajaniemi, S., and Kurkijärvi, U. (2007). Pharmaceutical Pricing and Reimbursement Information Finland. Available at: http://ppri.oebig.at/Downloads/Results/Finland_ PPRI_2007.pdf [Accessed 2 August 2010].
60. Prosser, H., Almond, S., and Walley, T. (2003). Influences on GPs' decision to prescribe new drugs - the importance of who says what. Fam. Pract. 20, 61-68.
61. Prosser, H., and Walley, T. (2005). A quali- tative study of GPs' and PCO stake- holders' views on the importance and influence of cost on prescribing. Soc. Sci. Med. 60, 1335-1346.
62. Rønning, M. (2002). A historical overview of ATC/DDD methodology. WHO Drug Inf. 16, 233-234.
63. Rønning, M., Blix, H. S., Harbø, B. T., and Strøm, H. (2000). Different versions of the anatomical therapeutic chemical classification system and the defined daily dose - are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56, 723-727.
64. Sakshaug, S., Furu, K., Karslstad, Ø., Rønning, M., and Skurtveit, S. (2007). Switching statins in Norway after new reimbursement policy - a nation- wide prescription study. Br. J. Clin. Pharmacol. 64, 476-481.
65. Schmacke, N., and Lauterberg, J. (2002). Criticism of new German chronic disease management is unfair. BMJ 325, 971.
66. Sermet, C., Andrieu, V., Godman, B., Van Ganse, E., Haycox, A., and Reynier, J. P. (2010). Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy 8, 7-24.
67. Shrank, W., Cox, E., Fischer, M., Mehta, J., and Choudhry, N. K. (2009). Patients' perception of generic medications. Health Affairs 28, 546-556.
68. Simoens, S. (2008a). Developing com- petitive and sustainable Polish generic medicines market. Croat. Med. J. 50, 440-448.
69. Simoens, S. (2008b). Generic medicine pricing in Europe: current issues and future perspective. J. Med. Econ. 11, 171-175.
70. Simoens, S. (2008c). Trends in generic pre- scribing and dispensing in Europe. Exp. Rev. Clin. Pharmacol. 1, 497-503.
71. Sjöborg, B., Bäckstrom, T., Arvidsson, L.-B., Andersén-Karlsson, E., Blomberg, L. B., Eiermann, B., Eliasson, M., Henriksson, K., Jacobsson, L., Jacobsson, U., Julander, M., Kaiser, P. O., Landberg, C., Larsson, J., Molin, B., and Gustafsson, L. L. (2007). Design and implementation of a point-of-care computerised system for drug therapy in Stockholm metro- politan health region - bridging the gap between knowledge and practice. Int. J. Med. Inform. 76, 497-506.
72. Stock, S., Schmit, H., Buscher, G., Gerber, A., Drabik, A., Graf, C., Lüngen, M., and Stollenwerk, B. (2010). Financial incentives in the German Statutory Health Insurance: new findings, new questions. Health Policy 96, 51-56.
73. Szecseny, J. (2003). Influence of attitudes and behaviour of GPs on prescribing costs. Qual. Saf. Health Care 12, 6-7.
74. Teixeira, I., and Vieira, I. (2008). Pharmaceutical Pricing and Reimbursement Information Portugal. Available at: http://ppri.oebig.at/Downloads/Results/Portugal_PPRI_2008.pdf [Accessed 2 August 2010].
75. Tilson, L., Bennett, K., and Barry, M. (2005). The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland. Eur. J. Health Econ. 50, 267-273.
76. Toth, F. (2010). Healthcare policies over the last 20 years: reforms and counter- reforms. Health Policy (New York) 95, 82-89.
77. Traulsen, J., and Almarsdóttir, A. (2005). The argument for pharmaceutical policy. Pharm. World Sci. 27, 7-12.
78. Usher-Smith, J., Ramsbottom, T., Pearmain, H., and Kirby, M. (2008). Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to cande- sartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484.
79. Valles, J.-A., Barreiro, M., Cereza, G., Ferro, J. J., Martínez, M. J., Escribà, J. M., Iglesias, B., Cucurull, E., and Barceló, E. (2003). A prospective multicentre study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy 65, 269-275.
80. Versantvoort, C., Maliepaard, M., and Lekkerkerker, F. (2008). Generics: what is the role of authorities. Neth. J. Med. 66, 62-66.
81. Vlahović-Palčevski, V., Gantumur, M., Radoševic, N., Palčevski, G., and Vander Stichele, R. (2010). Coping with changes in the defined daily dose in a longitudinal drug consump- tion database. Pharm. World Sci. 32, 125-129.
82. Von Ferber, L., Bausch, J., Koster, I., Schubert, I., and Ihle, P. (1999). Pharmacotherapeutic circles. Pharmacoeconomics 16, 273-283.
83. Walley, T., Folino-Gallo, P., Schwabe, U., and Van Ganse, E. (2004a). Variations and increase in use of statins across Europe: data from administrative databases. BMJ 328, 385-386.
84. Walley, T., Folino-Gallo, P., Schwabe, U., Van Ganse, E., Stephens, P. and Euro Med Stat Group. (2004b). Comparison of national adminis- trative and commercial databases to monitor expenditure and costs of statins across. Europe. Eur. J. Clin. Pharmacol. 60, 503-511.
85. Watkins, C., Harvey, I., Carthy, P., Moore, L., Robinson, E., and Brawn, R. (2003). Attitudes and behaviour of general practioners and their prescribing costs: a national cross sectional survey. Qual. Saf. Health Care 12, 29-34.
86. Wessling, A., and Lundin, D. (2006). The Review of Drugs Against Disease Caused by Acid Stomach - A Summary. Solna: Pharmaceuticals Benefits Board [online]. Available at: http://www.tlv.se/Upload/Genomgangen/summary- stomach-acid.pdf [Accessed 5 July 2010].
87. Wettermark, B., Godman, B., Andersson, K., Gustafsson, L. L., Haycox, A., and Bertele' V. (2008). Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550.
88. Wettermark, B., Godman, B., Neovius, M., Mellgren, T. O., and Kahan, T. (2010a). Initial effects of a reimbursement restriction to improve the cost-effec- tiveness of antihypertensive treatment. Health Policy 94, 221-229.
89. Wettermark, B., Persson, M. E., Wilking, N., Kalin, M., Korkmaz, S., Hjemdahl, P., Godman, B., Petzold, M., and Gustafsson, L. L. for the Regional Drug Expert Consortium. (2010b). Forecasting drug utilization and expend- iture in a metropolitan health region. BMC Health Services Research 10:128. doi: 10.1186/1472-6963-10-128
90. Wettermark, B., Pehrsson, A., Juhasz-Haverinen, M., Veg, A., Edlert, M., Törnwall-Bergendahl, G., Almkvist, H., Godman, B., Granath, F., and Bergman, U. (2009a). Financial incen- tives linked to self-assessment of pre- scribing patterns - a new approach for quality improvement of drug prescrib- ing in primary care. Qual. Prim. Care 17, 179-189.
91. Wettermark, B., Godman, B., Jacobsson, B., and Haaijer-Ruskamp, F. (2009b). Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 1-11.
92. World Health Organization. (2003). Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. Available at: http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf [Accessed 20 July 2010].
93. World Health Organization. (2009). Guidelines for ATC Classification and DDD Assignment 2009. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Available at: www.whocc.no [Accessed 20 July 2010].